Key Points
- Director Ian Clark sold 14,180 Guardant Health shares at an average price of $158.92, generating approximately $2.25 million. His remaining direct ownership fell 82.66% to 2,975 shares.
- Guardant Health shares opened at $163.18, with a one-year range of $43.66 to $176.58 and a market capitalization of approximately $21.9 billion. Institutional investors own 92.6% of the stock.
- Analyst sentiment remains largely positive: the stock has a “Moderate Buy” consensus rating and a $183.78 average price target, despite one sell rating.
Guardant Health, Inc. (NASDAQ:GH - Get Free Report) Director Ian Clark sold 14,180 shares of Guardant Health stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $158.92, for a total transaction of $2,253,485.60. Following the completion of the sale, the director directly owned 2,975 shares of the company's stock, valued at approximately $472,787. This trade represents a 82.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Guardant Health Price Performance
Shares of GH opened at $163.18 on Thursday. Guardant Health, Inc. has a one year low of $43.66 and a one year high of $176.58. The company has a market cap of $21.90 billion, a PE ratio of -46.76 and a beta of 1.60. The stock has a 50-day moving average of $145.75 and a 200-day moving average of $114.50.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC lifted its holdings in Guardant Health by 14.5% in the 2nd quarter. GAMMA Investing LLC now owns 965 shares of the company's stock worth $145,000 after buying an additional 122 shares during the period. First Pacific Financial increased its stake in shares of Guardant Health by 33.1% during the first quarter. First Pacific Financial now owns 559 shares of the company's stock valued at $52,000 after buying an additional 139 shares during the period. Xponance LLC raised its holdings in shares of Guardant Health by 2.1% during the fourth quarter. Xponance LLC now owns 9,630 shares of the company's stock valued at $984,000 after acquiring an additional 199 shares in the last quarter. Danske Bank A S raised its holdings in shares of Guardant Health by 20.0% during the fourth quarter. Danske Bank A S now owns 1,200 shares of the company's stock valued at $123,000 after acquiring an additional 200 shares in the last quarter. Finally, Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna lifted its stake in Guardant Health by 1.9% in the fourth quarter. Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna now owns 11,000 shares of the company's stock worth $1,124,000 after acquiring an additional 200 shares during the period. 92.60% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
GH has been the topic of a number of research reports. Royal Bank Of Canada upped their target price on Guardant Health from $185.00 to $200.00 and gave the stock an "outperform" rating in a research report on Friday, July 31st. Weiss Ratings restated a "sell (d-)" rating on shares of Guardant Health in a research note on Friday, July 17th. Citigroup upped their price objective on shares of Guardant Health from $150.00 to $215.00 and gave the stock a "buy" rating in a report on Wednesday, July 8th. Sanford C. Bernstein raised their price objective on shares of Guardant Health from $175.00 to $200.00 and gave the company an "outperform" rating in a research note on Thursday, July 2nd. Finally, Barclays boosted their target price on shares of Guardant Health from $150.00 to $200.00 and gave the stock an "overweight" rating in a research report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $183.78.
Get Our Latest Research Report on Guardant Health
About Guardant Health
(
Get Free Report)
Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health's mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.
The company's flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
